How Does Cardiovascular Disease First Present in Women and Men? Incidence of 12 Cardiovascular Diseases in a Contemporary Cohort of 1,937,360 People

Julie George, Eleni Rapsomaniki, Mar Pujades-Rodriguez, Anoop Dinesh Shah, Spiros Denaxas, Emily Herrett, Liam Smeeth, Adam Timmis, Harry Hemingway, Julie George, Eleni Rapsomaniki, Mar Pujades-Rodriguez, Anoop Dinesh Shah, Spiros Denaxas, Emily Herrett, Liam Smeeth, Adam Timmis, Harry Hemingway

Abstract

Background: Given the recent declines in heart attack and stroke incidence, it is unclear how women and men differ in first lifetime presentations of cardiovascular diseases (CVDs). We compared the incidence of 12 cardiac, cerebrovascular, and peripheral vascular diseases in women and men at different ages.

Methods and results: We studied 1 937 360 people, aged ≥ 30 years and free from diagnosed CVD at baseline (51% women), using linked electronic health records covering primary care, hospital admissions, acute coronary syndrome registry, and mortality (Cardiovascular Research Using LInked Bespoke Studies and Electronic Records [CALIBER] research platform). During 6 years median follow-up between 1997 and 2010, 114 859 people experienced an incident cardiovascular diagnosis, the majority (66%) of which were neither myocardial infarction nor ischemic stroke. Associations of male sex with initial diagnoses of CVD, however, varied from strong (age-adjusted hazard ratios, 3.6-5.0) for abdominal aortic aneurysm, myocardial infarction, and unheralded coronary death (particularly >60 years), through modest (hazard ratio, 1.5-2.0) for stable angina, ischemic stroke, peripheral arterial disease, heart failure, and cardiac arrest, to weak (hazard ratio <1.5) for transient ischemic attack, intracerebral hemorrhage, and unstable angina, and inverse (0.69) for subarachnoid hemorrhage (all P<0.001).

Conclusions: The majority of initial presentations of CVD are neither myocardial infarction nor ischemic stroke, yet most primary prevention studies focus on these presentations. Sex has differing associations with different CVDs, with implications for risk prediction and management strategies.

Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01164371.

Keywords: aging; cardiovascular diseases; electronic health records; incidence; population; risk factors; sex.

© 2015 The Authors.

Figures

Figure 1.
Figure 1.
Age and sex distribution of 60 155 events in men and 54 704 in women representing the initial presentation of a wide range of CVDs. CHD indicates coronary heart disease; CVD, cardiovascular disease; NOS, not otherwise specified; and SCD, sudden cardiac death.
Figure 2.
Figure 2.
Hazard ratios of men in comparison with women for initial presentation of 12 different cardiovascular diseases among a population of 1.93 million adults. CHD indicates coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; NOS, not otherwise specified; and SCD, sudden cardiac death.
Figure 3.
Figure 3.
Hazard ratios for men in comparison with women for initial presentation of 12 cardiovascular diseases by baseline age group among a population of 1.93 million adults. CHD indicates coronary heart disease; CI, confidence interval; HR, hazard ratio; NOS, not otherwise specified; and SCD, sudden cardiac death.

References

    1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation. 2013;127:e6–e245. doi: 10.1161/CIR.0b013e31828124ad.
    1. Murphy NF, MacIntyre K, Capewell S, Stewart S, Pell J, Chalmers J, Redpath A, Frame S, Boyd J, McMurray JJ. Hospital discharge rates for suspected acute coronary syndromes between 1990 and 2000: population based analysis. BMJ. 2004;328:1413–1414. doi: 10.1136/bmj.38111.650741.F7.
    1. Beaglehole R, Ebrahim S, Reddy S, Voûte J, Leeder S Chronic Disease Action Group. Prevention of chronic diseases: a call to action. Lancet. 2007;370:2152–2157. doi: 10.1016/S0140-6736(07)61700-0.
    1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913. doi: 10.1016/S0140-6736(02)11911-8.
    1. Anand SS, Islam S, Rosengren A, Franzosi MG, Steyn K, Yusufali AH, Keltai M, Diaz R, Rangarajan S, Yusuf S INTERHEART Investigators. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J. 2008;29:932–940. doi: 10.1093/eurheartj/ehn018.
    1. Hyvärinen M, Qiao Q, Tuomilehto J, Söderberg S, Eliasson M, Stehouwer CD. The difference between acute coronary heart disease and ischaemic stroke risk with regard to gender and age in Finnish and Swedish populations. Int J Stroke. 2010;5:152–156. doi: 10.1111/j.1747-4949.2010.00423.x.
    1. Kappert K, Böhm M, Schmieder R, Schumacher H, Teo K, Yusuf S, Sleight P, Unger T ONTARGET/TRANSCEND Investigators. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET). Circulation. 2012;126:934–941. doi: 10.1161/CIRCULATIONAHA.111.086660.
    1. Blumenthal D, Tavenner M. The “meaningful use” regulation for electronic health records. N Engl J Med. 2010;363:501–504. doi: 10.1056/NEJMp1006114.
    1. Gaziano JM. The evolution of population science: advent of the mega cohort. JAMA. 2010;304:2288–2289. doi: 10.1001/jama.2010.1691.
    1. Pujades-Rodriguez M, George J, Shah AD, Rapsomaniki E, Denaxas S, West R, Smeeth L, Timmis A, Hemingway H. Heterogeneous associations between smoking and a wide range of initial presentations of cardiovascular disease in 1937360 people in England: lifetime risks and implications for risk prediction. Int J Epidemiol. 2015;44:129–141. doi: 10.1093/ije/dyu218.
    1. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, White IR, Caulfield MJ, Deanfield JE, Smeeth L, Williams B, Hingorani A, Hemingway H. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet. 2014;383:1899–1911. doi: 10.1016/S0140-6736(14)60685-1.
    1. Pujades-Rodriguez M, Timmis A, Stogiannis D, Rapsomaniki E, Denaxas S, Shah A, Feder G, Kivimaki M, Hemingway H. Socioeconomic deprivation and the incidence of 12 cardiovascular diseases in 1.9 million women and men: implications for risk prediction and prevention. PLoS One. 2014;9:e104671. doi: 10.1371/journal.pone.0104671.
    1. Herrett E, Shah AD, Boggon R, Denaxas S, Smeeth L, van Staa T, Timmis A, Hemingway H. Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study. BMJ. 2013;346:f2350. doi: 10.1136/bmj.f2350.
    1. Denaxas SC, George J, Herrett E, Shah AD, Kalra D, Hingorani AD, Kivimaki M, Timmis AD, Smeeth L, Hemingway H. Data resource profile: cardiovascular disease research using linked bespoke studies and electronic health records (CALIBER). Int J Epidemiol. 2012;41:1625–1638. doi: 10.1093/ije/dys188.
    1. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, Deanfield J, Smeeth L, Timmis A, Hemingway H. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. Lancet Diabetes Endocrinol. 2015;3:105–113. doi: 10.1016/S2213-8587(14)70219-0.
    1. Gallagher AM, Puri S, Staa TV. Linkage of the General Practice Research Database (GPRD) with other data sources. Pharmacoepidemiol Drug Saf. 2011:S230–S364.
    1. Mathur R, Bhaskaran K, Chaturvedi N, Leon DA, vanStaa T, Grundy E, Smeeth L. Completeness and usability of ethnicity data in UK-based primary care and hospital databases. J Public Health (Oxf) 2014;36:684–692. doi: 10.1093/pubmed/fdt116.
    1. Lewis JD, Bilker WB, Weinstein RB, Strom BL. The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf. 2005;14:443–451. doi: 10.1002/pds.1115.
    1. Thompson SG, Pyke SD, Hardy RJ. The design and analysis of paired cluster randomized trials: an application of meta-analysis techniques. Stat Med. 1997;16:2063–2079. doi: 10.1002/(SICI)1097-0258(19970930)
    1. Harrell FE, Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–387. doi: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>;2-4.
    1. Department of Health. Cardiovascular Disease Outcomes Strategy: Improving outcomes for people at risk or with cardiovascular disease. 2013. . Accessed September 19, 2014.
    1. Leening MJ, Ferket BS, Steyerberg EW, Kavousi M, Deckers JW, Nieboer D, Heeringa J, Portegies ML, Hofman A, Ikram MA, Hunink MG, Franco OH, Stricker BH, Witteman JC, Roos-Hesselink JW. Sex differences in lifetime risk and first manifestation of cardiovascular disease: prospective population based cohort study. BMJ. 2014;349:g5992. doi: 10.1136/bmj.g5992.
    1. Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE, Redgrave JN, Bull LM, Welch SJ, Cuthbertson FC, Binney LE, Gutnikov SA, Anslow P, Banning AP, Mant D, Mehta Z Oxford Vascular Study. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet. 2005;366:1773–1783. doi: 10.1016/S0140-6736(05)67702-1.
    1. Baena-Díez JM, Vidal-Solsona M, Byram AO, González-Casafont I, Ledesma-Ulloa G, Martí-Sans N. The epidemiology of cardiovascular disease in primary care. the Zona Franca Cohort study in Barcelona, Spain. Rev Esp Cardiol. 2010;63:1261–1269.
    1. Canoui-Poitrine F, Luc G, Juhan-Vague I, Morange PE, Arveiler D, Ferrieres J, Amouyel P, Bingham A, Montaye M, Ruidavets JB, Haas B, Evans A, Ducimetiere P, Empana JP PRIME Study Group. Respective contribution of conventional risk factors and antihypertensive treatment to stable angina pectoris and acute coronary syndrome as the first presentation of coronary heart disease: the PRIME Study. Eur J Cardiovasc Prev Rehabil. 2009;16:550–555. doi: 10.1097/HJR.0b013e32832c88d1.
    1. Glynn RJ, Rosner B. Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. Am J Epidemiol. 2005;162:975–982. doi: 10.1093/aje/kwi309.
    1. Ducimetière P, Ruidavets JB, Montaye M, Haas B, Yarnell J PRIME Study Group. Five-year incidence of angina pectoris and other forms of coronary heart disease in healthy men aged 50-59 in France and Northern Ireland: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study. Int J Epidemiol. 2001;30:1057–1062. doi: 10.1093/ije/30.5.1057.
    1. Social Exclusion Task Force. Improving the Way We Meet the Primary Health Care Needs of the Socially Excluded. London: Cabinet Office; 2010.
    1. Manolio TA, Weis BK, Cowie CC, Hoover RN, Hudson K, Kramer BS, Berg C, Collins R, Ewart W, Gaziano JM, Hirschfeld S, Marcus PM, Masys D, McCarty CA, McLaughlin J, Patel AV, Peakman T, Pedersen NL, Schaefer C, Scott JA, Sprosen T, Walport M, Collins FS. New models for large prospective studies: is there a better way? Am J Epidemiol. 2012;175:859–866. doi: 10.1093/aje/kwr453.
    1. Collins R. What makes UK Biobank special? Lancet. 2012;379:1173–1174. doi: 10.1016/S0140-6736(12)60404-8.
    1. Risch N, Schaefer C. Kaiser Permanente Research Program on Genes, Environment and Health. 2011. . Accessed September 19, 2014.
    1. National Research Council (US) Committee on A Framework for Developing a New Taxonomy of Disease. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington, DC: National Academies Press;; 2013.
    1. Lauer MS. Time for a creative transformation of epidemiology in the United States. JAMA. 2012;308:1804–1805. doi: 10.1001/jama.2012.14838.
    1. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol. 2010;69:4–14. doi: 10.1111/j.1365-2125.2009.03537.x.
    1. Burns EM, Rigby E, Mamidanna R, Bottle A, Aylin P, Ziprin P, Faiz OD. Systematic review of discharge coding accuracy. J Public Health (Oxf) 2012;34:138–148. doi: 10.1093/pubmed/fdr054.
    1. Payne RA, Abel GA, Simpson CR. A retrospective cohort study assessing patient characteristics and the incidence of cardiovascular disease using linked routine primary and secondary care data. BMJ Open. 2012;2:e000723. doi: 10.1136/bmjopen-2011-000723.
    1. Marma AK, Berry JD, Ning H, Persell SD, Lloyd-Jones DM. Distribution of 10-year and lifetime predicted risks for cardiovascular disease in US adults: findings from the National Health and Nutrition Examination Survey 2003 to 2006. Circ Cardiovasc Qual Outcomes. 2010;3:8–14. doi: 10.1161/CIRCOUTCOMES.109.869727.
    1. Hippisley-Cox J, Coupland C, Robson J, Brindle P. Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database. BMJ. 2010;341:c6624. doi: 10.1136/bmj.c6624.
    1. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, Newby LK, Piña IL, Roger VL, Shaw LJ, Zhao D, Beckie TM, Bushnell C, D’Armiento J, Kris-Etherton PM, Fang J, Ganiats TG, Gomes AS, Gracia CR, Haan CK, Jackson EA, Judelson DR, Kelepouris E, Lavie CJ, Moore A, Nussmeier NA, Ofili E, Oparil S, Ouyang P, Pinn VW, Sherif K, Smith SC, Jr, Sopko G, Chandra-Strobos N, Urbina EM, Vaccarino V, Wenger NK. Effectiveness-based guidelines for the prevention of cardiovascular disease in women–2011 update: a guideline from the American Heart Association. Circulation. 2011;123:1243–1262. doi: 10.1161/CIR.0b013e31820faaf8.
    1. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497. doi:10.1001/jama.285.19.2486.
    1. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007;335:136. doi: 10.1136/bmj.39261.471806.55.
    1. Goff DC, Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Sr, Gibbons R, Greenland P, Lackland DT, Levy D, O’Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC, Jr, Sorlie P, Stone NJ, Wilson PWF. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S49–S73.
    1. Turnbull F Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527–1535. doi: 10.1016/S0140-6736(03)14739-3.
    1. JBS3 Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart. 2014;100(suppl):ii1–ii67.
    1. Aaronson KD, Cowger J. Heart failure prognostic models: why bother? Circ Heart Fail. 2012;5:6–9. doi: 10.1161/CIRCHEARTFAILURE.111.965848.
    1. Hippisley-Cox J, Coupland C, Brindle P. Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. BMJ. 2013;346:f2573. doi: 10.1136/bmj.f2573.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir